Highlights Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:16:09 2026-01-12 am EST			5-day change	1st Jan Change
895.05 ^INR	+0.02%		-2.92%	-2.11%

Jan. 09	FDA approves first generic robenacoxib tablet for postoperative pain in cats	RE
Jan. 02	Zydus Lifesciences' Luxembourg-Based Subsidiary Auroralux Gets Dissolved	MT

Highlights

Jan. 09	FDA approves first generic robenacoxib tablet for postoperative pain in cats	RE
Dec. 24	Zydus Lifesciences and Sterling Biotech extend API business acquisition closing to June 30	RE
Dec. 23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
Dec. 19	Zydus Lifesciences Signs Pact to Launch Cancer-Risk Assessment Diagnostic Tests in India	MT
Dec. 18	Zydus Lifesciences Limited Signs an Exclusive Agreement with Myriad Genetics	CI
Dec. 10	Zydus Lifesciences Launches Denosumab Biosimilar	MT
Dec. 09	Zydus Lifesciences launches biosimilar denosumab 120 mg SC	RE
Dec. 09	Zydus Lifesciences Limited Launches Biosimilar Denosumab 120 Mg Sc - Protecting Bone Health in Cancer Patients	CI
Dec. 09	Formycon, Zydus Sign Exclusive Deal for Keytruda Biosimilar in US, Canada	MT
Dec. 09	Formycon Secures Additional Commercialization Partnership for Keytruda Biosimilar	DP
Dec. 04	Zydus Lifesciences Gets US FDA's Establishment Inspection Report for Jarod, India Unit	MT
Dec. 04	Zydus Lifesciences receives EIR for injectable facility located at Jarod	RE
Nov. 27	Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg	CI
Nov. 26	Zydus and RK Pharma Enter into an Exclusive Licensing and Commercialization Agreement for a Novel 505(B)(2) Product of Supportive Oncology Treatment for the USA Market	CI
Nov. 26	Zydus Signs Exclusive Licensing Deal with US-based RK Pharma for Supportive Oncology Treatment Drug	MT
Nov. 25	Indian benchmark shares open higher on Fed rate cut optimism	RE
Nov. 25	Zydus Lifesciences Limited Receives Final Approval from United States Food and Drug Administration for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg	CI
Nov. 14	Zydus Lifesciences Limited Receives Final Approval from Usfda for Leuprolide Acetate Injection, 14 Mg/2.8Ml (1 Mg/0.2 Ml) Multiple-Dose Vial	CI
Nov. 13	Zydus Lifesciences Limited Receives Final Approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg	CI
Nov. 10	Zydus Lifesciences Gets Chinese Regulator's Approval for Depression Drug	MT
Nov. 10	Zydus Lifesciences Limited Receives Approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg	CI
Nov. 07	Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Olaparib Tablets, 100 Mg and 150 Mg	CI
Nov. 06	Zydus Lifesciences Consolidated Net Profit Rises in Fiscal Q2; Shares Down 3%	MT
Nov. 06	Zydus Lifesciences Sept-quarter consol net profit 12.59 billion rupees	RE
Nov. 06	Zydus Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Highlights

Filters